抗淋巴管生成治疗结直肠癌研究进展

doi:10.3969/j.issn.2095-378X.2021.01.018

摘要/Abstract

摘要： 肿瘤淋巴管生成是肿瘤淋巴管内皮细胞增殖、迁移、淋巴管新生并受淋巴管生成因子及其受体调控的多基因、多信号通路调控的复杂过程。在肿瘤淋巴转移中发挥重要作用,并与患者不良预后相关。随着对淋巴管生成及其内皮标志物的深入研究,人们对结直肠癌淋巴管转移的分子机制有了更清晰的认识,亦为针对肿瘤淋巴管生成的抗肿瘤淋巴管生成治疗提供了新的靶标。文章就肿瘤淋巴管生成及其分子调控机制、结直肠癌淋巴转移以及抗结直肠癌淋巴管生成作一综述。

关键词: 结直肠癌, 淋巴管生成, 淋巴管转移

Abstract: Tumor lymphangiogenesis is a complex process of tumor lymphatic endothelial cell proliferation, migration, and lymphangiogenesis. It is regulated by various signaling pathways, lymphangiogenic factors, and their receptors, which plays an important role in tumor lymphatic metastasis, and is related to the poor prognosis of patients. With the in-depth study of lymphangiogenesis and its endothelial markers, the molecular mechanism of lymphatic metastasis in colorectal cancer has been better understood, and new anti-tumor lymphangiogenesis treatments have been developed. The present paper reviewed studies of tumor lymphangiogenesis and its molecular regulation mechanisms, colorectal cancer lymphatic metastasis, and anti-lymphangiogenesis in colorectal cancer.

Key words: Colorectal cancer, Lymphangiogenesis, Lymphatic metastasis

中图分类号:

R735.3

王晖, 王芳涛, 范跃祖. 抗淋巴管生成治疗结直肠癌研究进展[J]. 外科研究与新技术, 2021, 10(1): 64-67.

WANG Hui, WANG Fangtao, FAN Yuezu. Research progress on anti-lymphangiogenesis in colorectal cancer[J]. Surgical Research and New Technique, 2021, 10(1): 64-67.

参考文献

[1] Ferlay J, Soerjomataram I, Dikshit R, et al.Cancer incidence and mortality worldwide: sources, method and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015,136(5): E359-386.
[2] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China,2015[J]. CA Cancer J Clin, 2016,66(2):115-132.
[3] Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al.Lymph node evaluation and survival after curative resection of colon cancer: systematic review[J]. J Natl Cancer Inst, 2007,99(6):433-441.
[4] Leung DW, Cachianes G, Kuang WJ, et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J]. Science, 1989,246(4935):1306-1309.
[5] Royston D, Jackson DG.Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma[J]. J Pathol, 2009,217(5):608-619.
[6] Saad RS, Kordunsky L, Liu YL, et al.Lymphatic microvessel density as prognostic marker in colorectal cancer[J]. Mod Pathol, 2006, 19(10):1317-1323.
[7] Nagahashi M, Ramachandran S, Rashid OM, et al.Lymphangiogenesis: a new player in cancer progression[J]. World J Gastroenterol, 2010,16(32):4003-4012.
[8] Tacconi C, Correale C, Gandelli A, et al.Vascular Endothelial Growth Factor C Disrupts the Endothelial Lymphatic Barrier to Promote Colorectal Cancer Invasion[J]. Gastroenterology, 2015,148(7):1438-1451.
[9] Zhong D, Li Y, Peng Q, et al.Expression of Tiam1 and VEGF-C correlates with lymphangiogenesis in human colorectal carcinoma[J]. Cancer Biol Ther, 2009,8(8): 689-695.
[10] Song J, Chen W, Cui X, et al.CCBE1 promotes tumor lymphangiogenesis and is negatively regulated by TGFβ signaling in colorectal cancer[J]. Theranostics, 2020,10(5): 2327-2341.
[11] Yin Q, Wang PP, Peng R, et al.MiR-19a enhances cell proliferation, migration, and invasiveness through enhancing lymphangiogenesis by targeting thrombospondin-1 in colorectal cancer[J]. Biochem Cell Biol, 2019,97(6):731-739.
[12] Liu AH, Liu LH, Lu H.Lnc RNA XIST facilitates proliferation and epithelial-mesenchymal transition of colorectal cancer cells through targeting miR‐486‐5p and promoting neuropilin‐2[J]. J Cell Physiol, 2018,234(8):13747-13761.
[13] Favier B, Alam A, Barron P, et al.Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration[J]. Blood, 2006,108(4):1243-1250.
[14] Ou JJ, Wei X, Peng Y, et al.Neuropilin-2 mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent signaling[J]. Cancer Lett, 2015,358(2):200-209.
[15] Ou JJ, Li J, Pan F, et al.Endostatin suppresses colorectal tumor-induced lymphangiogenesis by inhibiting expression of fibronectin extra domain A and integrin α9[J]. J Cell Biochem, 2011,112(8):2106-2114.
[16] Ou JJ, Deng J, Wei X, et al.Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells[J]. Stem Cell Res, 2013,11(2):820-833.
[17] Xiang LS, Xie GF, Ou JJ, et al.The Extra Domain A of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway[J]. PLoS ONE, 2012,7(4):e35378.
[18] Du B, Yang ZY, Zhong XY, et al.Metastasis-associated protein 1 induces VEGF-C and facilitates lymphangiogenesis in colorectal cancer[J]. World J Gastroenterol, 2011,17(9): 1219-1226.
[19] Li ZJ, Ying XJ, Chen HL, et al.Insulin-like growth factor-1 induces lymphangiogenesis and facilitates lymphatic metastasis in colorectal cancer[J]. World J Gastroenterol, 2013,19(43): 7788-7794.
[20] Stacker SA, Williams SP, Karnezis T, et al.Lymphangiogenesis and lymphatic vessel remodelling in cancer[J]. Nat Rev Cancer, 2014,14(3):159-172.
[21] Li X, Liu B, Xiao J, et al.Roles of VEGF-C and Smad4 in the lymphangiogenesis, lymphatic metastasis, and prognosis in colon cancer[J]. J Gastrointest Surg, 2011,15(11):2001-2010.
[22] Sun B, Zhou YM, Fang YT, et al.Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes[J]. Int J Cancer, 2019,145(6):1648-1659.
[23] Vellinga TT, Kranenburg O, Frenkel N, et al.Lymphangiogenic gene expression is associated with 24 lymph node recurrence and poor prognosis after partial hepatectomy for colorectal liver metastasis[J]. Ann Surg, 2017,266(5):765-771.
[24] Schutz FA, Choueiri TK, Sternberg CN.Pazopanib: clinical development of a potent anti-angiogenic drug[J]. Crit Rev Oncol Hematol, 2011,77(3):163-171.
[25] Zhu GW, Zhao M, Han QH, et al.Pazopanib inhibits tumor growth, lymph-node metastasis and lymphangiogenesis of an orthotopic mouse of colorectal cancer[J]. Cancer Genom Proteom, 2020,17(2):131-139.
[26] Lui ZC, Ma Q, Wang XH, et al.Inhibiting tumor growth of colorectal cancer by blocking the expression of vascular endothelial growth factor receptor 3 using interference vector-based RNA interference[J]. Int J Mol Med, 2010,25(1): 59-64.
[27] Li H, Lai ZJ, Yang H, et al.Hedyotis diffusa Willd. inhibits VEGF-C-mediated lymphangiogenesis in colorectal cancer via multiple signaling pathways[J]. Oncol Rep, 2019,42(3): 1225-1236.
[28] Lin JM, Feng JY, Jin YY, et al.Pien Tze Huang suppresses VEGF-C-mediated lymphangiogenesis in colorectal cancer[J]. Oncol Rep, 2016,36(6):3568-3576.
[29] Liu ZY, Qiu HO, Yuan XJ, et al.Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin[J]. Int J Oncol, 2012,41(5):1762-1772.
[30] Saif MW, Knost JA, Chiorean EG, et al.Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer[J]. Cancer Chemoth Pharm, 2016,78(4):815-824.
[31] Li J, Qin SK, Xu RH, et al.Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2015,16(6):619-629.
[32] Sundlisaeter E, Røsland GV, Hertel JK, et al.Increased lymphatic vascular density is seen before colorectal cancers reach stage Ⅱ and growth factor FGF-2 is downregulated in tumor tissue compared with normal mucosa[J]. APMIS, 2009,117(3):212-221.